LONDON – Immunocore Ltd. has opened a Phase IIa trial of its T-cell cancer vaccine, IMGgp100, after demonstrating immune responses and evidence of tumor shrinkage in some of the 31 patients with late-stage melanoma who took part in the Phase I single-dose study.